NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 358 filers reported holding NOVOCURE LTD in Q4 2020. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $742,850 | -33.2% | 17,900 | -3.2% | 0.01% | -37.5% |
| Q1 2023 | $1,112,590 | -17.6% | 18,500 | +0.5% | 0.02% | -23.8% |
| Q4 2022 | $1,349,640 | -3.5% | 18,400 | 0.0% | 0.02% | -8.7% |
| Q3 2022 | $1,398,000 | +9.9% | 18,400 | +0.5% | 0.02% | +15.0% |
| Q2 2022 | $1,272,000 | -16.1% | 18,300 | 0.0% | 0.02% | 0.0% |
| Q1 2022 | $1,516,000 | +8.6% | 18,300 | -1.6% | 0.02% | +17.6% |
| Q4 2021 | $1,396,000 | -35.0% | 18,600 | +0.5% | 0.02% | -41.4% |
| Q3 2021 | $2,149,000 | -50.1% | 18,500 | -4.6% | 0.03% | -47.3% |
| Q2 2021 | $4,304,000 | +68.7% | 19,400 | +0.5% | 0.06% | +52.8% |
| Q1 2021 | $2,551,000 | -26.7% | 19,300 | -4.0% | 0.04% | -26.5% |
| Q4 2020 | $3,478,000 | +63.6% | 20,100 | +5.2% | 0.05% | +40.0% |
| Q3 2020 | $2,126,000 | +89.7% | 19,100 | +1.1% | 0.04% | +66.7% |
| Q2 2020 | $1,121,000 | +29.0% | 18,900 | +46.5% | 0.02% | +10.5% |
| Q1 2020 | $869,000 | – | 12,900 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $26,344,000 | 8.01% |
| HARTLINE INVESTMENT CORP/ | 318,109 | $23,884,000 | 3.27% |
| Deep Track Capital, LP | 550,000 | $41,294,000 | 2.92% |
| MORGAN JESS S & CO INC | 43,975 | $3,302,000 | 2.03% |
| Taylor Frigon Capital Management LLC | 46,376 | $3,482,000 | 1.09% |
| Darsana Capital Partners LP | 258,937 | $19,441,000 | 0.90% |
| Private Harbour Investment Management & Counsel, LLC | 13,562 | $1,018,000 | 0.81% |
| Rhenman & Partners Asset Management AB | 120,387 | $9,610,000 | 0.64% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $751,000 | 0.50% |
| Baillie Gifford | 9,615,168 | $721,906,000 | 0.40% |